Ziska Pharmaceuticals Ltd.: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Ziska Pharmaceuticals Ltd.?

Yes. FDA’s import refusal records list 3 refused shipment lines declared as made by Ziska Pharmaceuticals Ltd. (India) whose FDA product code names tirzepatide and semaglutide, from Apr 14, 2025 to May 4, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Spellings in FDA records
Ziska Pharmaceuticals Ltd.; ZISKA PHARMACEUTICALS
Country
India
City in FDA records
Gazipur; Bangladesh
FEI numbers on the lines
3033302267, 3040975874
Refused lines
3
Lines with an Import Alert 66-80 API or powder code
0
Drugs named in the product codes
Tirzepatide, Semaglutide
Refusal dates
Apr 14, 2025 to May 4, 2026

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Ziska Pharmaceuticals Ltd. is on it.

Refused shipment lines

FDA refusal chargesShipment ID
May 4, 2026India61PCL74 TIRZEPATIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).1FX-0874542-3/10002/1
Dec 12, 2025India61PCL74 TIRZEPATIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-8924302-9/10003/1
Apr 14, 2025India61PCK72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-6313515-8/11/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).3

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

3 lines from FDA files read Nov 15, 2026.